Contravir Pharmaceuticals Incorporated (NASDAQ:CTRV) Can’t Be More Risky. Short Interest Increased

September 12, 2017 - By Kurt Siggers

 Contravir Pharmaceuticals Incorporated (NASDAQ:CTRV) Can't Be More Risky. Short Interest Increased

The stock of Contravir Pharmaceuticals Incorporated (NASDAQ:CTRV) registered an increase of 2.31% in short interest. CTRV’s total short interest was 5.48 million shares in September as published by FINRA. Its up 2.31% from 5.35M shares, reported previously. With 588,900 shares average volume, it will take short sellers 9 days to cover their CTRV’s short positions. The short interest to Contravir Pharmaceuticals Incorporated’s float is 9.25%.

About 387,524 shares traded. ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) has declined 14.63% since September 12, 2016 and is downtrending. It has underperformed by 31.33% the S&P500.

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $38.47 million. The Firm focuses on the development of antiviral drugs for the treatment of Hepatitis B virus infections. It currently has negative earnings. The Firm develops a range of compounds to treat HBV infection, which include CMX157 and CRV431.

More notable recent ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) news were published by: which released: “ContraVir Pharmaceuticals: Potentially Undervalued” on April 18, 2017, also with their article: “ContraVir Pharmaceuticals Announces Participation at the 19th Annual Rodman …” published on September 05, 2017, published: “ContraVir Pharmaceuticals Announces Issuance of New US Patent for Expansion of …” on August 21, 2017. More interesting news about ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) were released by: and their article: “ContraVir Pharmaceuticals Receives HBV IND Approval for Tenofovir Exalidex …” published on September 11, 2017 as well as‘s news article titled: “ContraVir Pharmaceuticals Announces Acceptance of Clinical Trial Application …” with publication date: September 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.